文献
J-GLOBAL ID:202002254119100371
整理番号:20A2200134
進行性非小細胞肺癌におけるプログラム死受容体1対プログラム細胞死リガンド1治療の相対的および絶対的利点:系統的レビューとメタ分析【JST・京大機械翻訳】
The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis
著者 (5件):
Yi Kun
(Department of Lymphoma and Hematology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, People’s Republic of China)
,
Zhu Qian
(Department of Intensive Care Unit, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China)
,
Kuang Yu-Kang
(Department of Thoracic Surgery, Jiangxi Cancer Hospital of Nanchang University, Nanchang, People’s Republic of China)
,
Jiang Si-Cong
(Department of Thoracic Surgery, Jiangxi Cancer Hospital of Nanchang University, Nanchang, People’s Republic of China)
,
Hu Hao
(Department of Radiation Therapy, General Hospital of Southern Theater Command of Chinese People’s Liberation Army, Guangzhou, People’s Republic of China)
資料名:
International Immunopharmacology
(International Immunopharmacology)
巻:
87
ページ:
Null
発行年:
2020年
JST資料番号:
T0026B
ISSN:
1567-5769
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)